

Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)

Technology appraisal guidance

Published: 30 March 2022

www.nice.org.uk/guidance/ta782

Contents

Advice	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm. This is because Stemline Therapeutics has confirmed that it does not intend to make an evidence submission for the appraisal. The company considers that there is not enough evidence to provide a submission for this appraisal.

Information

If NHS organisations wish to consider tagraxofusp for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-4536-8

Accreditation

